Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all PDCD1 (Pembrolizumab Biosimilar) products
- PDCD1 (Pembrolizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Pembrolizumab Biosimilar, Human PD-1 Monoclonal Antibody
- Specificity
- The in vivo grade pembrolizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1 or PD1), antagonizing its interaction with its known ligands PD-L1 or PDL1, and PD-L2 or PDL2.
- Characteristics
- Recombinant Humanized IgG4 Monoclonal Antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab biosimilar was produced in the pembrolizumab biosimilar CHO stable cell line.
- Isotype
- IgG4 kappa
-
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pembrolizumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- PDCD1 (Pembrolizumab Biosimilar)
- Abstract
- PDCD1 (Pembrolizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- What is Pembrolizumab biosimilar research grade? Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. Pembrolizumab Biosimilar uses the same protein sequences as the therapeutic antibody pembrolizumab.
-
You are here:
